MindMed Confirms 'Emerging Growth Company' Status in 8-K Filing

TL;DR

**MindMed is officially an 'emerging growth company,' meaning less SEC red tape but also less public info for investors.**

AI Summary

Mind Medicine (MindMed) Inc. filed an 8-K on January 8, 2024, primarily to disclose that it is an "emerging growth company." This designation, under the Securities Act of 1933 and the Securities Exchange Act of 1934, allows the company to take advantage of reduced reporting requirements. For investors, this means MindMed will have less stringent disclosure obligations, which could impact the transparency of information available about the company's operations and financial health.

Why It Matters

This filing confirms MindMed's status as an emerging growth company, which means it benefits from reduced regulatory burdens, potentially saving costs but also offering less public disclosure for investors.

Risk Assessment

Risk Level: low — The filing itself is a routine disclosure of company status and does not introduce new financial or operational risks.

Analyst Insight

Investors should be aware that MindMed's 'emerging growth company' status means less frequent and detailed disclosures compared to larger, more established companies, which could require more independent research to stay informed.

Key Numbers

• 001-40360 — Commission File Number (MindMed's unique identifier with the SEC)
• 212-220-6633 — Business Phone Number (MindMed's contact number)

Key Players & Entities

• Mind Medicine (MindMed) Inc. (company) — the registrant filing the 8-K
• January 8, 2024 (date) — date of earliest event reported and filing date
• British Columbia, Canada (company) — state or other jurisdiction of incorporation for MindMed
• 001-40360 (dollar_amount) — MindMed's Commission File Number
• MNMD (company) — trading symbol for MindMed's Common Shares
• The Nasdaq Stock Market LLC (company) — exchange where MindMed's Common Shares are registered

Forward-Looking Statements

• MindMed will continue to operate with reduced reporting requirements due to its emerging growth company status. (Mind Medicine (MindMed) Inc.) — high confidence, target: 2025-01-08

FAQ

Filing Documents

• mnmd-20240108.htm (8-K) — 44KB
• mnmd-ex99_1.htm (EX-99.1) — 34KB
• img158589805_0.jpg (GRAPHIC) — 5KB
• 0000950170-24-002705.txt ( ) — 210KB
• mnmd-20240108.xsd (EX-101.SCH) — 27KB
• mnmd-20240108_htm.xml (XML) — 5KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 8,2024, Mind Medicine (MindMed) Inc. (the “Company”) issued a press release providing a corporate update and 2024 outlook. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or the Exchange Act, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, or the Securities Act. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing with the U.S. Securities Exchange Commission, or the SEC, made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated January 8, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. MIND MEDICINE (MINDMED) INC. Date: January 8, 2024 By: /s/ Robert Barrow Name: Robert Barrow Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR